Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: Application to Huntington's disease
Source abstract
Abstract
The potential treatments for neurodegenerative disorders will be revolutionized by the transplantation of stem cells or neuronal progenitors derived from these cells. It is however crucial to better monitor their proliferation, improve their survival and differentiation and hence ameliorate their engraftment after transplantation. To direct stem cell fate, a delicate control of gene expression through RNA interference (RNAi) is emerging as a safe epigenetic approach. The development of novel biomaterials (nano and microcarriers) capable of delivering proteins, nucleic acids and cells, open the possibility to regulate cell fate while achieving neuroprotection and neurorepair and could be applied to Huntington's disease. This review first provides an overview of stem cell therapy for the neurodegenerative disorder Huntington's disease. Within that context, an integrative discussion follows of the control of stem cell behaviour by RNAi delivered by different nanocarriers in vitro prior to their transplantation. Finally, combined in vivo strategies using stem cells, biomaterials and epigenetic cell regulation are reported.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Pluripotent Stem Cells Research · Neuroscience and Neural Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk: multisource ascertainment of BC HD patients10.1002/mds.25717 ↗
2. Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review10.1186/1471-2458-14-653 ↗
3. Epidemiology of Huntington disease: first post- HTT gene analysis of prevalence in Italy: prevalence of Huntington disease in Italy
4. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease10.1038/ng0893-398 ↗
5. Autopsy-proven Huntington's disease with 29 trinucleotide repeats10.1002/mds.21195 ↗
6. Laboratory guidelines for Huntington disease genetic testing10.1086/301846 ↗
7. Metabolism in HD – still a relevant mechanism?10.1002/mds.25992 ↗
8. Huntington's disease and striatal signaling10.3389/fnana.2011.00055 ↗
9. Huntington disease: pathogenesis and treatment10.1016/j.ncl.2014.09.003 ↗
10. Molecular mechanisms and potential therapeutical targets in Huntington's disease10.1152/physrev.00041.2009 ↗
11. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease report of the guideline development subcommittee of the American academy of neurology10.1212/WNL.0b013e318263c443 ↗
12. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation10.1016/S0140-6736(00)03310-9 ↗
13. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study10.1016/S1474-4422(06)70381-7 ↗
14. Stem cell transplantation for Huntington's disease10.1016/j.expneurol.2006.11.007 ↗
15. Development of human striatal anlagen after transplantation in a patient with Huntington's disease10.1016/j.expneurol.2008.06.003 ↗
16. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease10.1136/jnnp.2007.142380 ↗
17. Cellular therapy and induced neuronal replacement for Huntington's Disease10.1007/s13311-011-0075-8 ↗
18. Huntington's disease: new frontiers for molecular and cell therapy10.2174/1389450053344975 ↗
19. 3D in vitro modeling of the central nervous system10.1016/j.pneurobio.2014.11.003 ↗
20. Tissue Engineering and Regenerative Medicine | National Institute of Biomedical Imaging and Bioengineering, (n.d.). http://www.nibib.nih.gov/science-education/science-topics/tissue-engineering-and-regenerative-medicine (Accessed 31.08.15).
21. Engineered N-cadherin and L1 biomimetic substrates concertedly promote neuronal differentiation, neurite extension and neuroprotection of human neural stem cells10.1016/j.actbio.2014.06.001 ↗
22. A cell encapsulation device for studying soluble factor release from cells transplanted in the rat brain10.1016/j.jconrel.2004.10.003 ↗
23. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats10.1073/pnas.0808488105 ↗
24. Homeobox genes Gsx1 and Gsx2 differentially regulate telencephalic progenitor maturation10.1073/pnas.1008824108 ↗
25. Human embryonic stem cell-derived gaba neurons correct locomotion deficits in quinolinic acid-lesioned mice10.1016/j.stem.2012.01.021 ↗
26. Generation of transplantable striatal projection neurons from human ESCs10.1016/j.stem.2012.03.004 ↗
27. Induction of pluripotent stem cells from adult human fibroblasts by defined factors10.1016/j.cell.2007.11.019 ↗
28. Induced pluripotent stem cell lines derived from human somatic cells10.1126/science.1151526 ↗
29. Induced pluripotent stem cells generated without viral integration10.1126/science.1162494 ↗
30. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome10.2183/pjab.85.348 ↗
31. Immunogenicity of induced pluripotent stem cells10.1038/nature10135 ↗
32. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery10.3389/fcell.2015.00002 ↗
33. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons10.1242/dev.084608 ↗
34. Human pluripotent stem cell differentiation into authentic striatal projection neurons10.1007/s12015-013-9441-8 ↗
35. Embryonic stem cells neural differentiation qualifies the role of Wnt/β-Catenin signals in human telencephalic specification and regionalization: human ESC telencephalic differentiation10.1002/stem.1462 ↗
36. Adult stem cells in neural repair: current options, limitations and perspectives10.4252/wjsc.v7.i2.477 ↗
37. Mammalian neural stem cells10.1126/science.287.5457.1433 ↗
38. Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease10.1177/096368970000900108 ↗
39. Neural stem/progenitor cells from the adult human spinal cord are multipotent and self-renewing and differentiate after transplantation10.1371/journal.pone.0027079 ↗
40. Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells10.1523/JNEUROSCI.16-15-04604.1996 ↗
41. Striatal transplantation in a transgenic mouse model of Huntington's Disease10.1006/exnr.1998.6926 ↗
42. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain10.1523/JNEUROSCI.19-14-05990.1999 ↗
43. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease10.1016/j.nbd.2004.01.016 ↗
44. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease10.1016/j.neuroscience.2006.01.025 ↗
45. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease10.1371/journal.pone.0064037 ↗
46. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease10.1186/1471-2202-13-97 ↗
47. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells
48. Adult cell therapy for brain neuronal damages and the role of tissue engineering10.1016/j.biomaterials.2009.11.084 ↗
49. Good manufacturing practices production of mesenchymal stem/stromal cells10.1089/hum.2010.197 ↗
50. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy10.1186/s13287-015-0240-9 ↗
51. Use of genetically altered stem cells for the treatment of Huntington's disease10.3390/brainsci4010202 ↗
52. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential10.1242/jcs.01103 ↗
53. Pharmacologically active microcarriers releasing glial cell line – derived neurotrophic factor: survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats10.1016/j.biomaterials.2006.12.021 ↗
54. EGF and bFGF pre-treatment enhances neural specification and the response to neuronal commitment of MIAMI cells10.1016/j.diff.2010.07.001 ↗
55. Organotypic cultures as tools for optimizing central nervous system cell therapies10.1016/j.expneurol.2013.07.012 ↗
56. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts10.1073/pnas.1100816108 ↗
57. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis10.1016/j.expneurol.2005.10.029 ↗
58. Comparative analysis of protein expression of three stem cell populations: models of cytokine delivery system in vivo10.1016/j.ijpharm.2011.12.041 ↗
59. G.E. Daviaud N, L.L. Lautram N, M.-M.C. Perez-Pinzon M, MODELING NIGROSTRIATAL DEGENERATION IN ORGANOTYPIC CULTURES WITHOUT NEUROTOXIC INJECTIONS; A NEW EX VIVO PARKINSON'S DISEASE D MODEL., Press. (n.d.).
60. The stem cell secretome and its role in brain repair10.1016/j.biochi.2013.06.020 ↗
61. W. Im, Lee, M. Kim, Transplantation of patient-derived adipose stem cells in YAC128 Huntington's disease transgenic mice, PLoS ONE. (n.d.). http://www.ncbi.nlm.nih.gov.gate2.inist.fr/pmc/articles/PMC2946829/?report=reader (Accessed 01.04.15).10.1371/currents.RRN1183 ↗
62. Slowed progression in models of huntington disease by adipose stem cell transplantation10.1002/ana.21788 ↗
63. Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease10.1371/journal.pone.0059438 ↗
64. Slowed progression in models of huntington disease by adipose stem cell transplantation10.1002/ana.21788 ↗
65. Mesenchymal stem cells expressing brain-derived neurotrophic factor enhance endogenous neurogenesis in an ischemic stroke model
66. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease: BDNF expression, behavior and striatum morphology10.1111/j.1601-183X.2012.00858.x ↗
67. Direct lineage reprogramming to neural cells10.1016/j.conb.2012.05.001 ↗
68. Direct conversion of fibroblasts to functional neurons by defined factors10.1038/nature08797 ↗
69. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions10.1016/j.stem.2011.07.002 ↗
70. Direct conversion of human fibroblasts to dopaminergic neurons10.1073/pnas.1105135108 ↗
71. MicroRNA-mediated conversion of human fibroblasts to neurons10.1038/nature10323 ↗
72. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts10.1038/nature10284 ↗
73. Regenerative medicine in Huntington's disease: current status on fetal grafts and prospects for the use of pluripotent stem cell10.1016/j.neurol.2014.10.007 ↗
74. Oligonucleotide therapeutic approaches for Huntington disease10.1172/JCI45130 ↗
75. Mutant huntingtin is present in neuronal grafts in huntington disease patients10.1002/ana.24174 ↗
76. Huntington's disease: an update of therapeutic strategies10.1016/j.gene.2014.11.022 ↗
77. Small non-coding RNAs as novel therapeutics10.2174/156652410791317048 ↗
78. Interfering with disease: a progress report on siRNA-based therapeutics10.1038/nrd2310 ↗
79. Regulation of insulin-like growth factor-dependent myoblast differentiation by Foxo forkhead transcription factors10.1083/jcb.200212107 ↗
80. Local delivery of siRNA using a biodegradable polymer application to enhance BMP-induced bone formation10.1016/j.biomaterials.2011.08.026 ↗
81. NRSF silencing induces neuronal differentiation of human mesenchymal stem cells10.1016/j.yexcr.2008.04.008 ↗
82. Regulation of neuronal traits by a novel transcriptional complex10.1016/S0896-6273(01)00371-3 ↗
83. Distinct profiles of REST interactions with its target genes at different stages of neuronal development10.1091/mbc.e05-07-0687 ↗
84. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis10.1016/j.cell.2005.03.013 ↗
85. Loss of RE-1 silencing factor in mesenchymal stem cell-derived dopamine progenitors induces functional maturity10.1016/j.mcn.2008.07.006 ↗
86. Directing neuronal differentiation of primary neural progenitor cells by gene knockdown approach10.1089/dna.2011.1557 ↗
87. Progress and problems with the use of viral vectors for gene therapy10.1038/nrg1066 ↗
88. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer10.1016/j.biomaterials.2008.04.036 ↗
89. Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium10.1016/j.biomaterials.2012.04.028 ↗
90. Recent advances in nanoparticle-mediated siRNA delivery10.1146/annurev-bioeng-071813-105119 ↗
91. Strategies for in vivo delivery of siRNAs10.2165/11534450-000000000-00000 ↗
92. Enhancement of neurite outgrowth in PC12 cells by iron oxide nanoparticles10.1016/j.biomaterials.2011.01.019 ↗
93. Neural cell adhesion molecule-stimulated neurite outgrowth depends on activation of protein kinase C and the Ras–mitogen-activated protein kinase pathway10.1523/JNEUROSCI.20-06-02238.2000 ↗
94. Nanocarriers in gene therapy: a review10.1166/jbn.2014.2044 ↗
95. Action and reaction: the biological response to siRNA and its delivery vehicles10.1038/mt.2011.294 ↗
96. Bioengineered nanoparticles for siRNA delivery: bioengineered nanoparticles for siRNA delivery10.1002/wnan.1233 ↗
97. D.A. Eppstein, P.L. Felgner, T.R. Gadek, G.H. Jones, R.B. Roman, Double coated liposome complex made up of polyanion and a lipid, Google Patents, 1990. http://www.google.com/patents/US4946787 (Accessed 02.04.15).
98. Nanocarriers: siRNA Delivery
99. Liposomes and lipid envelope-type systems for systemic siRNA delivery10.2174/138161282131151013185850 ↗
100. Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells10.1186/ar2436 ↗